Myovant Sciences Ltd. reported that its lead candidate, relugolix, met its primary efficacy endpoint and all six secondary endpoints in a phase III study of men with advanced prostate cancer, adding new strength to the asset's story, analysts said. Read More
DUBLIN – Crispr Therapeutics AG has delivered what appears, so far at least, to be a safe, functional cure for the first patient enrolled in each of its phase I/II trials of lead CRISPR/Cas9 gene editing therapy CTX-001, in beta-thalassemia and in sickle cell disease. Read More
While Burt Adelman has been in Boston since 1991, it wasn’t until he joined Novo Ventures Inc. about four years ago that he realized there was often no way to tie the area’s drug development together into something resembling a cohesive whole. Read More
Cytomx Therapeutics Inc. CEO Sean McCarthy said earlier this month that the firm was “not ready to guide on specific response rates” that the company hopes for in the phase II study with anti-PD-L1 Probody CX-072 in combination with ipilimumab, or ipi (Yervoy, Bristol-Myers Squibb Co.) in patients with relapsed refractory melanoma. Read More
Researchers at the RIKEN Center for Integrative Medical Science (IMS) and Keio University School of Medicine (KUSM) in Japan have discovered that people ages 110 or longer, the so-called supercentenarians, have elevated blood levels of CD4+ cytotoxic T lymphocytes (CTLs). Read More
LONDON – After a long haul to market, recent approvals and initial commercial successes of advanced cell and gene therapies are shifting the balance of power between biotech and pharma in dealmaking. Read More
A team led by researchers at Washington State University (WSU) has developed a nanoparticle technology to deliver cell-killing drugs to shut down the overactive immune response that can cause damage or death in diseases like stroke and sepsis without affecting other cell types or compromising the immune system. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations. Read More